Skip to main
ORKA

ORKA Stock Forecast & Price Target

ORKA Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oruka Therapeutics is a promising biopharmaceutical company with strong potential for success in their treatment of psoriasis and other inflammatory conditions. The company has a solid pipeline of drugs, including ORKA-001 and ORKA-002, which have shown promising results in Phase 1 and 2 trials. Potential risks include delays in clinical trials and competition, but with sufficient funding and potential commercial partnerships, Oruka appears to have a positive future ahead.

Bears say

Oruka Therapeutics is facing significant risks in its drug development programs, including potential unexpected outcomes, regulatory uncertainty, and competition in a complex and price-sensitive market. With only one program in Phase 2 clinical trials and no revenue from product sales, the company's financials are heavily reliant on external funding and the success of its clinical trials. This, combined with the highly competitive landscape in the I&I market, puts it at a disadvantage and warrants a negative outlook on the stock.

ORKA has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oruka Therapeutics Inc (ORKA) Forecast

Analysts have given ORKA a Strong Buy based on their latest research and market trends.

According to 11 analysts, ORKA has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oruka Therapeutics Inc (ORKA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.